Bupivacaine R-Gel (Prod 6101)






About Bupivacaine R-Gel (Prod 6101)

Royer has developed its R-Gel technology platform to deliver bupivacaine over a sustained period of at least 2 weeks, in order to treat post-operative pain associated with the iliac crest donor site. The matrix could be injected into the surgical site following autograft procurement and would cure in situ. Product available pending FDA approval.

Request Product Information

Disclaimer:

OrthopaedicLIST.com is a list of products and services. Every effort is made to keep this listing as accurate and current as possible. Companies and individuals are encouraged to notify us of errors and omissions. We will respond to such messages of correction in a timely fashion, as our workload permits.

We are non-judgmental of products listed. We are not in the business of evaluating products. We have not evaluated these products. We make no representations as to the quality, effectiveness, suitability or appropriateness of any of the products listed.

As an important component of the service function of OrthopaedicLIST.com, some products continue to be listed that are no longer manufactured and may not be available. We will identify them as such when possible. This allows users to find special instruments and/or components for removal, modification, and/or revision of those products.